Ir para o conteúdo principal

Vor Biopharma (NASDAQ: VOR) — Perfil da empresa, notícias e dados financeiros

Logo de Vor Biopharma
VOR Vor Biopharma
Vor Biopharma primary media
Perfil da empresa

Vor Biopharma

Vor Biopharma (NASDAQ:VOR) focuses on revolutionizing the treatment of cancer by modifying patients' hematopoietic stem cells to make them invisible to targeted therapies, potentially reducing or eliminating the side effects of these treatments. Its operations are primarily centered on the research and development of pioneering cell therapies aimed at improving the lives of patients battling cancer. Among its projects is the innovative VOR33, a treatment designed to facilitate targeted cancer therapy with minimized harm to non-cancerous cells. Vor Biopharma's objectives include advancing its research into clinical trials, expanding its portfolio of cell therapy candidates, and forging partnerships that enhance its technological capabilities and accelerate the development of its therapies. Through these endeavors, Vor Biopharma seeks to deliver groundbreaking treatments that transform cancer care.

Resumo

Public USParticipação acionária
2015Ano de fundação
168Funcionários
Cambridge, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Newton, US

Produtos e/ou serviços de Vor Biopharma

  • Engineered hematopoietic stem cell (eHSC) therapies targeting blood cancers.
  • VOR33, a treatment designed to remove CD33-expressing cells to enable targeted therapies.
  • Collaborations to develop CAR-T cell therapies enhancing adoptive cell transfer treatments.
  • Research in gene editing technologies to improve safety and efficacy of cell-based therapies.
  • Developing antibody-based drugs for precise targeting of cancer cells.
  • Partnerships aimed at advancing the manufacturing and scalability of cell therapies.

equipe executiva do Vor Biopharma

  • Jean-Paul KressChairman, President & CEO
  • Sandesh MahatmeChief Business Officer & CFO
  • Robert AngStrategic Advisor
  • Siddhartha MukherjeeScientific Founder & Chairman of Scientific Advisory Board
  • Adi OsovskyGeneral Counsel
  • Carol LincolnHead of Human Resources
  • Dallan MurrayChief Commercial Officer
  • Navid Z. KhanChief Medical Affairs Officer
  • Jeremy SokoloveChief Medical Officer

Principais indicadores financeiros

Resultados divulgados pela Vor Biopharma, em USD.

Cap. de mercado
1,2 bi
Receita (TTM)
0
P/L
0.1
LPA (diluído, TTM)
180.2
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Vor Biopharma
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-371,6 mi-696 mi
0-121,2 mi-116,9 mi
0-126 mi-117,9 mi
0-93,4 mi-92,1 mi